EMA Authorised: Zoledronic Acid Accord (zoledronic acid monohydrate) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Zoledronic Acid Accord (zoledronic acid monohydrate) for hypercalcemia, prevention of fractures in bone disorders, and cancer-related bone co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hypercalcemia
• Osteoporosis

Drugs mentioned

• Zoledronic Acid Accord (zoledronic acid monohydrate)

Snippet

Status: Authorised. Therapeutic area: Hypercalcemia;Fractures, Bone;Cancer. MAH: Accord Healthcare S.L.U.. Decision date: 23/02/2026